Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06387225 Not yet recruiting - Cardiac Arrest Clinical Trials

Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients

HYPERION-2
Start date: September 1, 2024
Phase:
Study type: Observational

Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers. To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial. It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.

NCT ID: NCT06387121 Not yet recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL), despite the achievements of chemotherapy and immunotherapy, the therapeutic outcomes are unsatisfactory in elderly or unfit patients. In recent years, tumor immunotherapy has demonstrated a high safety and efficacy profile in refractory Ph- B-ALL patients. These findings suggest that the advancement of immunotherapy application may be an important approach to improve patient survival. In this study, we propose a treatment approach that combines immuno-targeted drugs with low-dose chemotherapy for newly diagnosed elderly or unfit patients with Ph- B-ALL, aiming to enhance the measurable residual disease (MRD)-negative complete remission (CR) rate measured through flow cytometry following induction therapy, reduce the risk of relapse, and ultimately improve patients' overall survival.

NCT ID: NCT06386471 Recruiting - Clinical trials for Cardiovascular Diseases

Personalized GI Motility Responses to Diet

Start date: March 7, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized, crossover, clinical trial is to link: 1) gastrointestinal motility patterns induced by acute consumption of whole and refined grains, 2) enteric microbial production of bioactive metabolites, and 3) circulating postprandial appearance of metabolites important to cardiometabolic health including glucose, triglycerides, and cholesterol. Participants will be asked to consume a Smartpill monitoring device that records metrics of gastrointestinal motility in response to whole or refined grains, monitor cardiometabolic metabolties over an 8 hour postprandial window, and provide a fecal sample for microbiome-related analyses.

NCT ID: NCT06386445 Not yet recruiting - Acute Kidney Injury Clinical Trials

Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT: Cohort Study

Start date: May 1, 2024
Phase:
Study type: Observational

This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.

NCT ID: NCT06386432 Not yet recruiting - Clinical trials for Cigarette Smoking-Related Carcinoma

EQQUAL-NM for the Promotion of Smoking Cessation in Sexual and Gender Minority Young Adults in New Mexico

Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial assesses the acceptability and efficacy of Empowered, Queer, Quitting, and Living--New Mexico (EQQUAL-NM), a smoking cessation intervention for sexual and gender minority young adults in New Mexico. Smoking prevalence among sexual and gender minority (SGM) adults in New Mexico is more than twice as high as non-SGM adults. Helping young adult tobacco users to quit is critical, yet there have been few efforts to develop tailored treatments specifically for this population. EQQUAL-NM is a digital smoking cessation intervention designed specifically for SGM young adult smokers in New Mexico and may help them quit smoking.

NCT ID: NCT06386354 Not yet recruiting - Clinical trials for Postoperative Complications

Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications

Porcerito
Start date: May 1, 2024
Phase:
Study type: Observational

The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient.

NCT ID: NCT06386315 Not yet recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

NCT ID: NCT06385977 Recruiting - Clinical trials for Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Risk Factors for Chronic Prostatitis Patients in Northwest China

Start date: January 2016
Phase:
Study type: Observational

The goal of this observational study is to learn about the risk factors of lifestyle, medication and sexual habits in adult chronic prostatitis / chronic pelvic pain syndrome patients. The main questions it aims to answer are: - Is lifestyle, medication, and sexual habits related to chronic prostatitis / chronic pelvic pain syndrome - Is there any medication available to protect men from chronic prostatitis / chronic pelvic pain syndrome. Participants will: - Independently receive a survey questionnaire on lifestyle, medication, and sexual habits. - Symptomatic individuals will undergo additional prostate fluid examination for diagnosis. Researchers will compare healthy adult males to see if there are differences on lifestyle, medication and sexual habits between the two groups.

NCT ID: NCT06385834 Not yet recruiting - Clinical trials for ST-segment Elevation Myocardial Infarction (STEMI)

The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

The aim of the study was to intervene in the Aerobic exercise time of patients with STEMI and to explore the optimal exercise time for STEMI patients

NCT ID: NCT06385808 Not yet recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia. The secondary purpose of the study was to observe the safety of MTBF regimen in these patients.